Avantor® Announces New J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease
Avantor announced the launch of two new products, J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease, aimed at optimizing the gene therapy harvest process. These products address biopharmaceutical demand for sustainable options while improving the efficiency and quality of viral particle harvests. The J.T.Baker® Cell Lysis Solution, a biodegradable alternative to Octoxynol-9, ensures low ecotoxicity and protects viral particles during processing. It also streamlines the harvest process by reducing contamination risks. In combination with J.T.Baker® Endonuclease, which removes residual impurities, these products offer scalable, efficient, and environmentally friendly solutions for gene therapy manufacturing.
- Avantor introduced J.T.Baker® Cell Lysis Solution, a biodegradable product reducing ecotoxicity concerns.
- The new J.T.Baker® Cell Lysis Solution improves viral vector release efficiency, enhancing gene therapy workflows.
- Combination of J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease streamlines the harvest process, reducing the number of steps and contamination risk.
- Products cater to growing biopharmaceutical demand for sustainable and scalable solutions.
- None.
Avantor's introduction of the J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease marks a significant step forward in the gene therapy manufacturing process. The replacement of Octoxynol-9 with a biodegradable and low ecotoxicity solution addresses growing regulatory and environmental concerns, particularly in the European market. This strategic move not only aligns Avantor with stringent REACH regulations but also contributes to a more sustainable bioprocessing environment. From a technical perspective, the high efficiency of viral vector release and the protection of viral particles from damage demonstrate substantial improvements in product performance.
The introduction of these products also implies potential cost savings through reduced bioburden risk and minimized need for pre-dilution and filtration steps. These benefits could result in increased adoption among biopharmaceutical manufacturers, thereby bolstering Avantor's market position in the life sciences sector.
The launch of Avantor's new J.T.Baker® solutions is poised to have a positive impact on the company's market dynamics. The gene therapy market is experiencing rapid growth, driven by advancements in personalized medicine and increasing FDA approvals for gene therapies. By offering products that enhance efficiency and sustainability, Avantor is tapping into this lucrative segment with a strong value proposition. The emphasis on sustainability is particularly noteworthy, as it caters to the rising demand from biopharmaceutical firms for environmentally friendly products. This could potentially lead to increased market share and customer loyalty.
Moreover, by providing ready-to-use solutions that streamline the manufacturing process, Avantor addresses key operational challenges faced by gene therapy manufacturers, which could translate to higher adoption rates and repeat business. The scalable and cGMP-grade nature of these products further enhances their appeal to a wide range of manufacturers, from small biotech firms to large pharmaceutical companies.
Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale
"These products help gene therapy manufacturers improve harvest while preserving the quality and integrity of highly valuable viral particles," said Benoit Gourdier, Executive Vice President of Bioscience Production at Avantor. "These products also respond to growing demand from biopharmaceutical customers for environmentally sustainable options."
Avantor scientists developed J.T.Baker® Cell Lysis Solution as a safe and effective alternative to Octoxynol-9, which is on the European Chemicals Agency's "substance of very high concern" list under REACH regulations given concerns that it is toxic to aquatic life when entering the environment through waste systems.
J.T.Baker® Cell Lysis Solution is biodegradable and exhibits low ecotoxicity when used in the upstream harvesting process to release adeno-associated virus (AAV) from host cells, a pivotal step in gene therapy workflows. Avantor® studies1 show that the solution improves the efficiency of viral vector release across a range of cell densities and temperatures while protecting the viral particles from damage during processing.
As a ready-to-use reagent that does not require refrigeration or advanced preparation, the J.T.Baker® Cell Lysis Solution streamlines the harvest process and minimizes contamination risk by eliminating the need for pre-dilution and filtration, significantly reducing bioburden risk. The solution's high-concentration formulation also lowers viscosity and foam generation to reclaim valuable bioreactor space.
Pairing J.T.Baker® Cell Lysis Solution with compatible J.T.Baker® Endonuclease — an enzyme that removes remaining impurities — can further reduce the number of steps at harvest, enabling a more efficient process. Working together to provide robust DNA clearance and reduced aggregation, these solutions can be customized for any scale with a wide range of cGMP grade size options.
Avantor's J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease are part of a full range of modular and scalable chemical and fluid handling solutions. For additional product information, please visit our web site.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Global Media Contact
Emily Collins
Vice President, External Communications
Avantor
332-239-3910
Emily.Collins@avantorsciences.com
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
1 Novel Cell Lysis Solution: Scaling up the harvest process while preserving what matters, Kroeger-Fahnestock, 2024
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-new-jtbaker-cell-lysis-solution-and-jtbaker-endonuclease-302186455.html
SOURCE Avantor and Financial News
FAQ
What new products has Avantor (AVTR) announced?
What is the release date for Avantor's (AVTR) new products?
How do Avantor's (AVTR) new products impact gene therapy manufacturing?
Why is J.T.Baker® Cell Lysis Solution considered environmentally friendly?
What benefits do J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease provide together?
What specific problem does J.T.Baker® Cell Lysis Solution address?
